Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer—a narrative review

BACKGROUND AND OBJECTIVE: First-line treatment options for patients with advanced non-small cell lung cancer (aNSCLC) whose tumors harbour anaplastic lymphoma kinase (ALK) gene rearrangements have rapidly evolved from chemotherapy, to the first in class ALK-targeted tyrosine kinase inhibitor (TKI) c...

Descripción completa

Detalles Bibliográficos
Autores principales: Chazan, Grace, Solomon, Benjamin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989801/
https://www.ncbi.nlm.nih.gov/pubmed/36895924
http://dx.doi.org/10.21037/tlcr-22-656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989801/
https://www.ncbi.nlm.nih.gov/pubmed/36895924
http://dx.doi.org/10.21037/tlcr-22-656

Ejemplares similares